Log in to search using one of your social media accounts:

 

Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration

Objectives: To investigate whether serum neurofilament light (NfL) concentration is increased in familial Alzheimer disease (FAD), both pre and post symptom onset, and whether it is associated with markers of disease stage and severity. Methods: We recruited 48 individuals from families with PSEN1 or APP mutations to a cross-sectional study: 18 had symptomatic Alzheimer disease (AD) and 30 were asymptomatic but at 50% risk of carrying a mutation. Serum NfL was measured using an ultrasensitive immunoassay on the single molecule array (Simoa) platform. Cognitive testing and MRI were performed; 33 participants had serial MRI, allowing calculation of atrophy rates. Genetic testing established mutation status. A generalized least squares regression model was used to compare serum NfL among symptomatic mutation carriers, presymptomatic carriers, and noncarriers, adjusting for age and sex. Spearman coefficients assessed associations between serum NfL and (1) estimated years to/from symptom onset (EYO), (2) cognitive measures, and (3) MRI measures of atrophy. Results: Nineteen of the asymptomatic participants were mutation carriers (mean EYO –9.6); 11 were noncarriers. Compared with noncarriers, serum NfL concentration was higher in both symptomatic (p
Source: Neurology - Category: Neurology Authors: Tags: Alzheimer's disease ARTICLE Source Type: research

Related Links:

Authors: Snitz BE, Wang T, Cloonan YK, Jacobsen E, Chang CH, Hughes TF, Kamboh MI, Ganguli M Abstract INTRODUCTION: We compared risk of progression from subjective cognitive decline (SCD) to mild cognitive impairment (MCI) in an academic memory clinic versus a population-based study. METHODS: Older adults presenting at a memory clinic were classified as SCD (n = 113) or as noncomplainers (n = 82). Participants from a population study were classified as SCD (n = 592) and noncomplainers (n = 589) based on a memory complaint score. Annual follow-up performed for 3 years. ...
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
While there are no drugs that can treat Alzheimer’s disease and reverse the memory and thinking problems it causes, a new study shows that some non-drug strategies may help to improve cognitive skills in some people with the illness. About 25% of people in the world are born with one copy of a gene, called APOE4, that is linked to a higher risk of developing Alzheimer’s. About 2% to 3% of the population has two copies of the gene — one from their mother and another from their father — that dramatically increases their risk for the disease. About 60% of those people will develop Alzheimer’s by ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Alzheimer's alzheimer's diet alzheimer's exericse alzheimer's genes alzheimer's lifestyle Brain diseases Genetics healthytime onetime Source Type: news
Can you remember what you had for dinner last night? How do you do it?byAlzheimer's Reading RoomThe temporal lobe,which contains the hippocampus, and the prefrontal cortex are important to episodic memory. This enables us to learn new information andremember recent events.The hippocampus is one of the first brain structures damaged in Alzheimer's disease.How Alzheimer's Affects the 4 Memory Systems of the BrainSubscribe to the Alzheimer's Reading - This is a Free Service - Join NowHow Your Brain Remembers What You Had for Dinner Last NightUC San Diego researchers find small sets of hippocampal neurons activate for each epi...
Source: Alzheimer's Reading Room, The - Category: Neurology Tags: brain memory memory systems of the brain remember research Source Type: blogs
This study is examining the combination of two novel interventions – transcranial direct current stimulation (tDCS) and cognitive remediation therapy – to protect against AD in patients with depression or mild cognitive impairment. The study is funded by Brain Canada and carried out by researchers in CAMH’s Geriatric Psychiatry Division in collaboration with Baycrest, St. Michael’s Hospital, Sunnybrook Health Sciences Centre and University Health Network. The Study in Context Solving the Brain Fitness Puzzle Is the Key to Self-Empowered Aging Important insights on the growing home use of tDCS...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Cognitive Neuroscience Health & Wellness Technology Alzheimers brain Brain-Fitness Brain-Training brain-training-exercises cognitive remediation cognitive-reserve dementia electrical stimulation mental-exercises Pfizer pharmace Source Type: blogs
This article is protected by copyright. All rights reserved.
Source: European Journal of Neuroscience - Category: Neuroscience Authors: Tags: Research Report Source Type: research
This article is part of the Special Issue “Vascular Dementia”. We propose that hyperhomocysteinemia (HHcy) results in a pro‐inflammatory response at the vasculature, which activates the matrix metalloproteinase MMP9. MMP9 subsequently cleaves the a‐b dystroglycan complex, leading to disruption of the astrocytic connection with the vasculature. MMP9 also degrades the dystrophin Dp71 anchoring complex, resulting in the down‐regulation of astrocytic end‐foot channels. The end result of the end‐foot disruption is impaired potassium homeostasis in the brain and impaired neurovascular coupling.
Source: Journal of Neurochemistry - Category: Neuroscience Authors: Tags: Review Source Type: research
One of the most commonly asked questions about cognitive issues is “Is it Alzheimer’s or dementia?” The short answer is, Alzheimer’s is one type of dementia. According to the Alzheimer’s Association, “Dementia is a general term for loss of memory and other mental abilities severe enough to interfere with daily life. It is caused by physical changes in the brain.” View complete slideshow about differences in the types of dementia: http://www.inforum.com/lifestyle/health/4385854-hospice-care-covered-medicare-other-insurance Minding Our Elders lets you know that you are...
Source: Minding Our Elders - Category: Geriatrics Authors: Source Type: blogs
DEMENTIA is an umbrella term for a collection of symptoms that result from damage to the brain caused by different diseases - for example Alzheimer ’s. There is currently no cure available, but expert believe there are ways of reducing the risk of it developing.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
In conclusion, death is a natural part of human existence, but human progress is essentially a story of overcoming undesirable natural limits. In the near future, technological progress might make it possible to stop natural biological death. Should humankind embrace such technology? Yes: Even though such technology would not be without risks, the risks are almost certainly manageable. The benefits of ending natural death, on the other hand, are immense. Death is an obstacle that is slowing down human progress. If we remove that obstacle, humankind could increase the speed of both its moral and its epistemic progress. ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
ConclusionAXD of NAWM might be an early marker of microstructural brain tissue changes occurring during the AD course and might be useful for assessing disease progression.Level of Evidence: 1Technical Efficacy: Stage 2J. Magn. Reson. Imaging 2017.
Source: Journal of Magnetic Resonance Imaging - Category: Radiology Authors: Tags: Original Research Source Type: research
More News: Alzheimer's | Brain | Dementia | Genetics | Men | Neurology | Study